HIV Mutation Detail Information

Virus Mutation HIV Mutation D368R


Basic Characteristics of Mutations
Mutation Site D368R
Mutation Site Sentence Mutation of the CD4-binding site (D368R/D368Kgp120, A281Tgp120) (Dosenovic et al., 2015, Horwitz et al., 2013, Olshevsky et al., 1990), the V3 glycan patch (N332A/N332Kgp120) (Horwitz et al., 2013, Mouquet et al., 2012), and the V2 apex epitope (N160Kgp120) (Walker et al., 2009), alone or in combination, did not abrogate SF5 or SF12 binding (Figure 2A).
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region gp120
Standardized Encoding Gene Env  
Genotype/Subtype HIV-1
Viral Reference "HIV-1YU2, HIV-1BG505"
Functional Impact and Mechanisms
Disease HIV Infections    
Immune -
Target Gene CD4   
Clinical and Epidemiological Correlations
Clinical Information Y
Treatment -
Location USA
Literature Information
PMID 31126879
Title Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Author Schoofs T,Barnes CO,Suh-Toma N,Golijanin J,Schommers P,Gruell H,West AP Jr,Bach F,Lee YE,Nogueira L,Georgiev IS,Bailer RT,Czartoski J,Mascola JR,Seaman MS,McElrath MJ,Doria-Rose NA,Klein F,Nussenzweig MC,Bjorkman PJ
Journal Immunity
Journal Info 2019 Jun 18;50(6):1513-1529
Abstract Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan-dominated epitope on Env's silent face and was potent against clade AE viruses, which are poorly covered by V3-glycan bNAbs. A 3.3A cryo-EM structure of a SF12-Env trimer complex showed additional contacts to Env protein residues by SF12 compared with VRC-PG05, the only other known donor-derived silentface antibody, explaining SF12's increased neutralization breadth, potency, and resistance to Env mutation routes. Asymmetric binding of SF12 was associated with distinct N-glycan conformations across Env protomers, demonstrating intra-Env glycan heterogeneity. Administrating SF12 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448(gp120) glycan. Effective bNAbs can therefore be raised against HIV-1 Env's silent face, suggesting their potential for HIV-1 prevention, therapy, and vaccine development.
Sequence Data MK722158-MK722171
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.